Sendi P - Search Results

1

Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection.

Sendi P, Palmer AJ, Gafni A, Battegay M. Sendi P, et al. Pharmacoeconomics. 2001;19(7):709-13. doi: 10.2165/00019053-200119070-00001. Pharmacoeconomics. 2001. PMID: 11548908

2

Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.

Sendi PP, Craig BA, Meier G, Pfluger D, Gafni A, Opravil M, Battegay M, Bucher HC. Sendi PP, et al. J Antimicrob Chemother. 1999 Dec;44(6):811-7. doi: 10.1093/jac/44.6.811. J Antimicrob Chemother. 1999. PMID: 10590283 Free article. Clinical Trial.

3

Opportunity costs and uncertainty in the economic evaluation of health care interventions.

Sendi P, Gafni A, Birch S. Sendi P, et al. Health Econ. 2002 Jan;11(1):23-31. doi: 10.1002/hec.641. Health Econ. 2002. PMID: 11788979

4

Modeling the socioeconomic impact of osteoporosis-related hip fractures in Switzerland.

Sendi P, Palmer AJ. Sendi P, et al. Osteoporos Int. 2000;11(1):92-4. doi: 10.1007/s001980050011. Osteoporos Int. 2000. PMID: 10663364 No abstract available.

5

Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.

Sendi PP, Bucher HC, Harr T, Craig BA, Schwietert M, Pfluger D, Gafni A, Battegay M. Sendi PP, et al. AIDS. 1999 Jun 18;13(9):1115-22. doi: 10.1097/00002030-199906180-00016. AIDS. 1999. PMID: 10397543

6

Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care.

Hirsch HH, Drechsler H, Holbro A, Hamy F, Sendi P, Petrovic K, Klimkait T, Battegay M. Hirsch HH, et al. Among authors: sendi p. Eur J Clin Microbiol Infect Dis. 2005 Nov;24(11):733-8. doi: 10.1007/s10096-005-0044-4. Eur J Clin Microbiol Infect Dis. 2005. PMID: 16328557

7

An opportunity cost approach to sample size calculation in cost-effectiveness analysis.

Gafni A, Walter SD, Birch S, Sendi P. Gafni A, et al. Among authors: sendi p. Health Econ. 2008 Jan;17(1):99-107. doi: 10.1002/hec.1244. Health Econ. 2008. PMID: 17497751

8

Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients.

Battegay M, Vernazza PL, Bernasconi E, Flepp M, Sendi P, Erb P, Malinverni R, Jaccard C, Morgenthaler S, Bedoucha V, Hirschel B; Swiss HIV Cohort Study. Battegay M, et al. Among authors: sendi p. HIV Med. 2001 Jan;2(1):35-42. doi: 10.1046/j.1468-1293.2001.00047.x. HIV Med. 2001. PMID: 11737374 Free article. Clinical Trial.

9

Starting or changing therapy - a prospective study exploring antiretroviral decision-making.

Fehr JS, Nicca D, Sendi P, Wolf E, Wagels T, Kiss A, Bregenzer T, Vernazza P, Jäger H, Spirig R, Battegay M; Swiss HIV Cohort Study. Fehr JS, et al. Among authors: sendi p. Infection. 2005 Aug;33(4):249-56. doi: 10.1007/s15010-005-4141-1. Infection. 2005. PMID: 16091895

10

Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study.

Sendi PP, Bucher HC, Craig BA, Pfluger D, Battegay M. Sendi PP, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):376-81. doi: 10.1097/00042560-199904010-00008. J Acquir Immune Defic Syndr Hum Retrovirol. 1999. PMID: 10096582 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters